Renal cell carcinoma

JAMA

Volumn 292, Issue 1, 2004, Pages 97-100

  Curti, Brendan D ^a,b  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CYCLOPHOSPHAMIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN PEPTIDE 96 COMPLEX; INTERLEUKIN 2; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CAUSE OF DEATH; CLINICAL GENETICS; CLINICAL TRIAL; DENDRITIC CELL; DRUG ACTIVITY; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FEVER; HEREDITY; HISTOPATHOLOGY; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; MALAISE; METABOLIC DISORDER; METASTASIS; NEPHRECTOMY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE; UREMIA; CANCER STAGING; GENETICS; KIDNEY TUMOR; MORTALITY; PROGNOSIS;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 3042820411     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.1.97     Document Type: Review

References (29)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-1631.
3. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. Baltimore, Md: Williams & Wilkins; 1996.
4. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163-2172.
5. Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994;54:2852-2855.
6. Gnarra JR, Zhou S, Merrill MJ, et al. Posttranscriptional regulation of vascular enclothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A. 1996;93: 10589-10594.
7. Doderlein A, Birch-Hirschfield FV. Embryonale drusengesch wulst der nierengegend im kindasalter. Sex Organe. 1894;3:88.
8. Reuter VE, Presti JC. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol. 2000;27:124-137.
9. Saika T, Ono Y, Hattori R, et al. Long-term outcome of laparoscopic radical nephrectomy for pathologic T1 renal cell carcinoma. Urology. 2003;62:1018-1023.
10. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol. 1986;136:376-379.
11. Montie JE, Stewart BH, Straffon RA, et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 1977;117:272-275.
12. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
13. Zisman A, Pantuck AJ, Dorey F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002;20:1368-1374.
14. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000;27:187-193.
15. Fisher RI, Rosenberg SA, Sznol M, et al. Highdose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am. 1997;3(suppl 1):S70-S72.
16. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy, phase III: randomised controlled trial. Lancet. 2004;363:594-599.
17. Fenton RG, Steis RG, Madara K, et al. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. J Immunother Emphasis Tumor Immunol. 1996;19:364-374.
18. Schwaab T, Tretter CP, Gibson JJ, et al. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J Urol. 2004;171: 1036-1042.
19. Gitlitz BJ, Belldegrun AS, Zisman A, et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003;26:412-419.
20. Cohen L, de Moor C, Parker PA, Amato RJ. Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. Urol Oncol. 2002;7:119-124.
21. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
22. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
23. Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol. 1999;162:1277-1281.
24. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol. 1994;12:206-212.
25. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17: 2530-2540.
26. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88:348-353.
27. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003; 97:1663-1671.
28. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811.
29. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma (RCC) response to interleukin-2-based therapy [abstract]. Proc Am Soc Clin Oncol. 2003;851:3420.